Develop business strategies Of Glaucoma-Pipeline Review, H1 2018
"The Report
Glaucoma-Pipeline Review, H1 2018 provides information on pricing,
market analysis, shares, forecast, and company profiles for key
industry participants. - MarketResearchReports.biz"
About
Glaucoma
Market
Global Markets Direct's latest
Pharmaceutical and Healthcare disease pipeline guide Glaucoma -
Pipeline Review, H1 2018, provides an overview of the Glaucoma
(Ophthalmology) pipeline landscape.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1672968
Glaucoma is a disease of the eye
in which fluid pressure within the eye rises. The exact cause of
optic nerve damage from glaucoma is not fully understood, but
involves mechanical compression and/or decreased blood flow of the
optic nerve. The most important risk factors include age, elevated
eye pressure, African ancestry, thin cornea, family history of
glaucoma. Signs and symptoms include eye pain, nausea and vomiting
(accompanying the severe eye pain), sudden onset of visual
disturbance, often in low light, blurred vision and reddening of the
eye.
Report Highlights
Global Markets Direct's
Pharmaceutical and Healthcare latest pipeline guide Glaucoma -
Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Glaucoma (Ophthalmology), complete
with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and
latest news and press releases.
The
Glaucoma (Ophthalmology) pipeline guide also reviews of key players
involved in therapeutic development for Glaucoma and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical,
Discovery and Unknown stages are 1, 1, 11, 20, 8, 58, 14 and 4
respectively. Similarly, the Universities portfolio in Phase I,
Preclinical and Discovery stages comprises 1, 10 and 3 molecules,
respectively.
Request
for TOC @
https://www.marketresearchreports.biz/reports/1672968/glaucoma-pipeline-review-h1-2018-market-research-reports/toc
Glaucoma (Ophthalmology) pipeline
guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage. The guide is built using data and information sourced from
Global Markets Directs proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings,
investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
Note: Certain content / sections
in the pipeline guide may be removed or altered based on the
availability and relevance of data.
Scope
- The pipeline guide provides a
snapshot of the global therapeutic landscape of Glaucoma
(Ophthalmology).
- The pipeline guide reviews
pipeline therapeutics for Glaucoma (Ophthalmology) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
- The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide features
descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key
companies involved in Glaucoma (Ophthalmology) therapeutics and
enlists all their major and minor projects.
- The pipeline guide evaluates
Glaucoma (Ophthalmology) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
- The pipeline guide reviews
latest news related to pipeline therapeutics for Glaucoma
(Ophthalmology)
Reasons to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective
R&D strategies.
- Recognize emerging players with
potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
- Find and recognize significant
and varied types of therapeutics under development for Glaucoma
(Ophthalmology).
- Classify potential new clients
or partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and its most promising
pipeline therapeutics.
- Formulate corrective measures
for pipeline projects by understanding Glaucoma (Ophthalmology)
pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential
and scope.
- Adjust the therapeutic portfolio
by recognizing discontinued projects and understand from the know-how
what drove them from pipeline.
View
Report @
https://www.marketresearchreports.biz/reports/1672968/glaucoma-pipeline-review-h1-2018-market-research-reports
Table of Contents
Table of Contents 2
Introduction 5
Glaucoma - Overview 6
Glaucoma - Therapeutics
Development 7
Glaucoma - Therapeutics Assessment
24
Glaucoma - Companies Involved in
Therapeutics Development 36
Glaucoma - Drug Profiles 62
Glaucoma - Dormant Projects 267
Glaucoma - Discontinued Products
273
Glaucoma - Product Development
Milestones 275
Appendix 285
List of Tables
Number of Products under
Development for Glaucoma, H1 2018
Number of Products under
Development by Companies, H1 2018
Number of Products under
Development by Universities/Institutes, H1 2018
Products under Development by
Companies, H1 2018
Products under Development by
Universities/Institutes, H1 2018
Number of Products by Stage and
Target, H1 2018
Number of Products by Stage and
Mechanism of Action, H1 2018
Number of Products by Stage and
Route of Administration, H1 2018
Number of Products by Stage and
Molecule Type, H1 2018
Glaucoma - Pipeline by AC Immune
SA, H1 2018
Glaucoma - Pipeline by Advanced
Refractive Technologies Inc, H1 2018
Glaucoma - Pipeline by Aerie
Pharmaceuticals Inc, H1 2018
Glaucoma - Pipeline by Aerpio
Therapeutics Inc, H1 2018
Glaucoma - Pipeline by Allergan
Plc, H1 2018
Glaucoma - Pipeline by Altacor
Ltd, H1 2018
Glaucoma - Pipeline by Amarantus
Bioscience Holdings Inc, H1 2018
Glaucoma - Pipeline by Amgen Inc,
H1 2018
Glaucoma - Pipeline by Annexon
Inc, H1 2018
Glaucoma - Pipeline by Astellas
Pharma Inc, H1 2018
Glaucoma - Pipeline by Bial -
Portela & Ca SA, H1 2018
Glaucoma - Pipeline by BioAxone
BioSciences Inc, H1 2018
Glaucoma - Pipeline by Bionure
Farma SL, H1 2018
Glaucoma - Pipeline by Can-Fite
BioPharma Ltd, H1 2018
Glaucoma - Pipeline by Chong Kun
Dang Pharmaceutical Corp, H1 2018
Glaucoma - Pipeline by D. Western
Therapeutics Institute Inc, H1 2018
Glaucoma - Pipeline by Dompe
Farmaceutici SpA, H1 2018
Glaucoma - Pipeline by Elsalys
Biotech SAS, H1 2018
Glaucoma - Pipeline by Eyevensys
SAS, H1 2018
Glaucoma - Pipeline by F.
Hoffmann-La Roche Ltd, H1 2018
Glaucoma - Pipeline by Fortress
Biotech Inc, H1 2018
Glaucoma - Pipeline by Gene Signal
International SA, H1 2018
Glaucoma - Pipeline by Glaukos
Corp, H1 2018
Glaucoma - Pipeline by Graybug
Vision Inc, H1 2018
Glaucoma - Pipeline by Han Wha
Pharma Co Ltd, H1 2018
Glaucoma - Pipeline by Handok Inc,
H1 2018
Glaucoma - Pipeline by HitGen LTD,
H1 2018
Glaucoma - Pipeline by Icon
Bioscience Inc, H1 2018
Glaucoma - Pipeline by ID Pharma
Co Ltd, H1 2018
Glaucoma - Pipeline by InMed
Pharmaceuticals Inc, H1 2018
Glaucoma - Pipeline by Inspyr
Therapeutics Inc, H1 2018
Glaucoma - Pipeline by Ironwood
Pharmaceuticals Inc, H1 2018
Glaucoma - Pipeline by Isarna
Therapeutics GmbH, H1 2018
Glaucoma - Pipeline by Kukje
Pharmaceutical Industry Co Ltd, H1 2018
Glaucoma - Pipeline by
Laboratorios SALVAT SA, H1 2018
Glaucoma - Pipeline by
Laboratorios Sophia SA de CV, H1 2018
Glaucoma - Pipeline by Lee's
Pharmaceutical Holdings Ltd, H1 2018
Glaucoma - Pipeline by MimeTech
Srl, H1 2018
Glaucoma - Pipeline by Nemus
Bioscience Inc, H1 2018
Glaucoma - Pipeline by Neurim
Pharmaceuticals Ltd, H1 2018
Glaucoma - Pipeline by NicOx SA,
H1 2018
Glaucoma - Pipeline by NoNO Inc,
H1 2018
Glaucoma - Pipeline by Novaliq
GmbH, H1 2018
Glaucoma - Pipeline by Novartis
AG, H1 2018
Glaucoma - Pipeline by Ocular
Therapeutix Inc, H1 2018
Glaucoma - Pipeline by Oculis ehf,
H1 2018
Glaucoma - Pipeline by Ohr
Pharmaceutical Inc, H1 2018
Glaucoma - Pipeline by Oncolys
BioPharma Inc, H1 2018
Glaucoma - Pipeline by Pivot
Pharmaceuticals Inc, H1 2018
Glaucoma - Pipeline by Profarma,
H1 2018
Glaucoma - Pipeline by Q BioMed
Inc, H1 2018
Glaucoma - Pipeline by Quark
Pharmaceuticals Inc, H1 2018
Glaucoma - Pipeline by Regeneron
Pharmaceuticals Inc, H1 2018
Glaucoma - Pipeline by Santen
Pharmaceutical Co Ltd, H1 2018
Glaucoma - Pipeline by Senju
Pharmaceutical Co Ltd, H1 2018
Glaucoma - Pipeline by Shire Plc,
H1 2018
Glaucoma - Pipeline by Sun Pharma
Advanced Research Company Ltd, H1 2018
Glaucoma - Pipeline by Sylentis
SAU, H1 2018
Glaucoma - Pipeline by Taejoon
Pharm Co Ltd, H1 2018
Glaucoma - Pipeline by TikoMed AB,
H1 2018
Glaucoma - Dormant Projects, H1
2018
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment